Skip to search formSkip to main contentSkip to account menu

iodine I 131 monoclonal antibody CC49

Known as: 131I-MOAB CC49, I 131 Monoclonal Antibody CC49, I131 MOAB CC49 
A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Biodistribution Study of 188 ReLabeled Trisuccin-HuCC 49 and Trisuccin-HuCC 49 ACa 2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer Xenografts
  • 2007
  • Corpus ID: 12189706
The t r ihydroxamate bifunctional chelating agent (BCA), trisuccin, has been shown to be a potential ligand for radiolabeling of… 
2002
2002
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Radioisotopes with moderate half-lives are essential for conventional radioimmunotherapy using tumor-selective MAbs which require… 
2001
2001
Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
The prospects of radiolabeled antibodies in cancer detection and therapy remain promising. However, efforts to achieve cures… 
1999
1999
Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors… 
1999
1999
Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
One of the problems in achieving cures with radioimmunotherapy is that hematological toxicity limits the quantity of radiolabeled… 
1997
1997
The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe.
A phase II study to evaluate the safety and efficacy of the 125I-radiolabeled anti-TAG-72 monoclonal antibody, CC49, as a… 
1997
1997
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Preclinical studies have demonstrated that recombinant IFN-alpha (rIFN-alpha) can enhance the tumor associated glycoprotein 72… 
Highly Cited
1995
Highly Cited
1995
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Monoclonal antibody (MAb) CC49 reacts with tumor-associated glycoprotein (TAG)-72, a human pancarcinoma antigen. In clinical… 
Highly Cited
1995
Highly Cited
1995
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
CC49 is a second-generation monoclonal antibody (MAb) that has high affinity for the tumor-associated pancarcinoma antigen tumor… 
1995
1995
Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer.
The ability to identify and expand effector cells with reactivity against tumor-associated antigens (TAA) is critical for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)